Cyclophophamide
Phase 3Small molecule
Cyclophophamide is one of 60 small molecule programs targeting Lymphoma. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Cyclophophamide
AAllogene Therapeutics
Phase 3
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
PEG-Intron
Merck & Co.Preclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
R-CHOP
IIncyte Biosciences Japan GK
Preclinical
JY231
SShenzhen Genocury Biotech Co., Ltd.
Preclinical
Inactivated Influenza Vaccine
SanofiPreclinical
Istodax
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cyclophophamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAllogene Therapeutics